litlas
Log inCreate account

Massimo Cristofanilli

Active 2001–2025

253
Papers
50,042
Citations
110
h-index
241
i10-index

Citations

Citations per year for Massimo Cristofanilli1926: 1 citations1964: 3 citations1971: 1 citations1994: 1 citations2001: 3 citations2002: 18 citations2003: 56 citations2004: 83 citations2005: 96 citations2006: 169 citations2007: 249 citations2008: 283 citations2009: 347 citations2010: 439 citations2011: 455 citations2012: 432 citations2013: 443 citations2014: 450 citations2015: 434 citations2016: 497 citations2017: 508 citations2018: 566 citations2019: 2,009 citations2020: 2,172 citations2021: 2,014 citations2022: 1,682 citations2023: 1,225 citations2024: 1,802 citations2025: 1,008 citations2026: 28 citations1927–1963: no citations, so these years are not shown1965–1970: no citations, so these years are not shown1972–1993: no citations, so these years are not shown1995–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,818 citing papers, 26.7% of this breakdownChina: 2,287 citing papers, 12.7% of this breakdownItaly: 1,085 citing papers, 6% of this breakdownUnited Kingdom: 949 citing papers, 5.3% of this breakdownGermany: 873 citing papers, 4.8% of this breakdownFrance: 776 citing papers, 4.3% of this breakdownSpain: 602 citing papers, 3.3% of this breakdownCanada: 508 citing papers, 2.8% of this breakdownJapan: 459 citing papers, 2.5% of this breakdownAustralia: 438 citing papers, 2.4% of this breakdownIndia: 400 citing papers, 2.2% of this breakdownSouth Korea: 387 citing papers, 2.1% of this breakdown
0%26.7%Other 24.9%

Institutions

Fields

  • Medicine53.2%
  • Biochemistry, Genetics and Molecular Biology37.2%
  • Engineering3%
  • Immunology and Microbiology2.9%
  • Computer Science0.9%
  • Materials Science0.8%
  • Other2%

Topics

  • Cancer Cells and Metastasis8%
  • Cancer Genomics and Diagnostics6.2%
  • Breast Cancer Treatment Studies6.1%
  • Advanced Breast Cancer Therapies5.5%
  • HER2/EGFR in Cancer Research4.8%
  • Cancer-related Molecular Pathways2.7%
  • Other66.7%

Coauthors

All papers

Open in search
  1. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Authors: Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, María Koehler, Dennis J. Slamon - The Lancet Oncology 2016 cited by 1,822

  2. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Authors: Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro, Igor Bondarenko, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Fabrice André, Kathy Puyana Theall, Xin Huang, C. Giorgetti, Cynthia Huang Bartlett, Massimo Cristofanilli - New England Journal of Medicine 2018 cited by 1,293

  3. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

    Authors: Massimo Cristofanilli, G. Thomas Budd, Matthew J. Ellis, Alison Stopeck, Jeri Matera, Michael Craig Miller, James M. Reuben, Gerald V. Doyle, W. Jeffrey Allard, Leon W.M.M. Terstappen, Daniel F. Hayes - New England Journal of Medicine 2004 cited by 4,584

  4. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

    Authors: Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice André, Attila Tordai, Jaime Mejia, W. Fraser Symmans, Ana M. González-Angulo, Bryan T. Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobágyi, Lajos Pusztai - Journal of Clinical Oncology 2008 cited by 2,906

  5. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Authors: Nicholas C. Turner, Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Cynthia Huang Bartlett, Ke Zhang, C. Giorgetti, Sophia Randolph, María Koehler, Massimo Cristofanilli - New England Journal of Medicine 2015 cited by 1,586

  6. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

    Authors: Ben O’Leary, Rosalind Cutts, Yuan Liu, Sarah Hrebien, Xin Huang, Kerry Fenwick, Fabrice André, Sibylle Loibl, Sherene Loi, Isaac García-Murillas, Massimo Cristofanilli, Cynthia Huang Bartlett, Nicholas C. Turner - Cancer Discovery 2018 cited by 667

  7. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives

    Authors: Eleonora Nicolò, Federica Giugliano, Liliana Ascione, Paolo Tarantino, Chiara Corti, Sara M. Tolaney, Massimo Cristofanilli, Giuseppe Curigliano - Cancer Treatment Reviews 2022 cited by 213

  8. The Landscape of Targeted Therapies in TNBC

    Authors: Elena Vagia, Devalingam Mahalingam, Massimo Cristofanilli - Cancers 2020 cited by 451

  9. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

    Authors: Nicholas C. Turner, Yuan Liu, Zhou Zhu, Sherene Loi, Marco Colleoni, Sibylle Loibl, Angela DeMichele, Nadia Harbeck, Fabrice André, Mohamed Amine Bayar, Stefan Michiels, Zhe Zhang, C. Giorgetti, Mónica Arnedos, Cynthia Huang Bartlett, Massimo Cristofanilli - Journal of Clinical Oncology 2019 cited by 464

  10. ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer

    Authors: Rokana Taftaf, Xia Liu, Salendra Singh, Yuzhi Jia, Nurmaa K. Dashzeveg, Andrew D. Hoffmann, Lamiaa El-Shennawy, Erika K. Ramos, Valery Adorno-Cruz, Emma J. Schuster, David Scholten, Dhwani Patel, Youbin Zhang, Andrew A. Davis, Carolina Reduzzi, Yue Cao, Paolo D’Amico, Yang Shen, Massimo Cristofanilli, William A. Müller, Vinay Varadan, Huiping Liu - Nature Communications 2021 cited by 265

  11. Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models

    Authors: Xia Liu, Rokana Taftaf, Madoka Kawaguchi, Ya-Fang Chang, Wenjing Chen, David Entenberg, Youbin Zhang, Lorenzo Gerratana, Simo Huang, Dhwani Patel, Elizabeth Tsui, Valery Adorno-Cruz, Steven M. Chirieleison, Yue Cao, Allison S. Harney, Shivani Patel, Antonia Patsialou, Yang Shen, Stefanie Avril, Hannah Gilmore, Justin D. Lathia, Derek W. Abbott, Massimo Cristofanilli, John S. Condeelis, Huiping Liu - Cancer Discovery 2018 cited by 411

  12. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

    Authors: Massimo Cristofanilli, Hope S. Rugo, Seock‐Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O’Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner - Clinical Cancer Research 2022 cited by 198

  13. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

    Authors: Charlotte Fribbens, Ben O’Leary, Lucy Kilburn, Sarah Hrebien, Isaac García-Murillas, Matthew Beaney, Massimo Cristofanilli, Fabrice André, Sherene Loi, Sibylle Loibl, John Jiang, Cynthia Huang Bartlett, María Koehler, Mitch Dowsett, Judith M. Bliss, Stephen Johnston, Nicholas C. Turner - Journal of Clinical Oncology 2016 cited by 718

  14. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Zefei Jiang, Wei Li, Xichun Hu, Qingyuan Zhang, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng, Zhongsheng Tong, Ying Cheng, Yueyin Pan, Yuping Sun, Hong Wang, Tao Ouyang, Kangsheng Gu, Jifeng Feng, Xiaojia Wang, Shubin Wang, Tianshu Liu, Jinghua Gao, Massimo Cristofanilli, Zhiqiang Ning, Xianping Lu - The Lancet Oncology 2019 cited by 267

  15. Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

    Authors: Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, Garrett M. Frampton, Funda Meric‐Bernstam, Ana M. González-Angulo, Jaime Ferrer-Lozano, José Alejandro Pérez Fidalgo, Massimo Cristofanilli, Henry Gómez, Carlos L. Arteaga, Jennifer M. Giltnane, Justin M. Balko, Maureen Cronin, Mirna Jarosz, James Sun, Matthew Hawryluk, Doron Lipson, Geoff Otto, Jeffrey S. Ross, Addie Dvir, Lior Soussan‐Gutman, Ido Wolf, Tamar Rubinek, Lauren Gilmore, Stuart J. Schnitt, Steven E. Come, Lajos Pusztai, Philip Stephens, Myles Brown, Vincent A. Miller - Clinical Cancer Research 2014 cited by 662

  16. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

    Authors: Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B. Hanker, Valerie M. Jansen, Joshua A. Bauer, Dhivya R. Sudhan, Ángel Guerrero‐Zotano, Sarah Croessmann, Yan Guo, Paula I. González-Ericsson, Kyung‐min Lee, Mellissa J. Nixon, Luis J. Schwarz, Melinda E. Sanders, Teresa C. Dugger, Marcelo Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O’Shaughnessy, Rebecca J. Nagy, Richard B. Lanman, Nadia Solovieff, Wei He, Michelle C. Miller, Fei Su, Yu Shyr, Ingrid A. Mayer, Justin M. Balko, Carlos L. Arteaga - Nature Communications 2019 cited by 419

  17. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

    Authors: Anne F. Schott, Lori J. Goldstein, Massimo Cristofanilli, Pier Adelchi Ruffini, Susan McCanna, James M. Reuben, Raymond P. Perez, Giraldo Kato, Max S. Wicha - Clinical Cancer Research 2017 cited by 240

  18. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

    Authors: Ben O’Leary, Sarah Hrebien, James P. Morden, Matthew Beaney, Charlotte Fribbens, Xin Huang, Yuan Liu, Cynthia Huang Bartlett, María Koehler, Massimo Cristofanilli, Isaac García-Murillas, Judith M. Bliss, Nicholas C. Turner - Nature Communications 2018 cited by 420

  19. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

    Authors: Erica L. Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, X. Cynthia, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D. Miller, Yara Abdou, Elizabeth C. Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Natalie Sinclair, Meredith Faggen, Caroline Block, Naomi Y. Ko, Ann H. Partridge, Wendy Y. Chen, Michelle K. DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J. Burstein, Meredith M. Regan, Sara M. Tolaney - Journal of Clinical Oncology 2024 cited by 109

  20. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

    Authors: Sabine Riethdorf, Herbert A. Fritsche, Volkmar Müller, Thomas Rau, Christian Schindlbeck, Brigitte Rack, Wolfgang Janni, Cornelia Coith, Katrin Beck, F. Jänicke, Summer Jackson, Terrie G. Gornet, Massimo Cristofanilli, Klaus Pantel - Clinical Cancer Research 2007 cited by 1,337

  21. Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

    Authors: Massimo Cristofanilli, Daniel F. Hayes, G. Thomas Budd, Mathew J. Ellis, Alison Stopeck, James M. Reuben, Gerald V. Doyle, Jeri Matera, W. Jeffrey Allard, Michael Craig Miller, Herbert A. Fritsche, Gabriel N. Hortobágyi, Leon W.M.M. Terstappen - Journal of Clinical Oncology 2005 cited by 1,135

  22. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatment

    Authors: Nicholas C. Turner, Cynthia Huang Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, X. Cynthia, Erica L. Mayer, Yeon Hee Park, Stephen B. Fox, Xiaochun Liu, Sasha McClain, François‐Clément Bidard - Future Oncology 2023 cited by 78

  23. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

    Authors: Massimo Cristofanilli, Jean‐Yves Pierga, James M. Reuben, Alfred Rademaker, Andrew A. Davis, Dieter Peeters, Tanja Fehm, Franco Nolè, Rafael Gisbert‐Criado, Dimitriοs Mavroudis, Salvatore Grisanti, Mario Giuliano, José Á. García-Sáenz, Justin Stebbing, Carlos Caldas, Paola Gazzaniga, Luís Manso, Rita Zamarchi, Ángela Fernández de Lascoiti, Leticia De Mattos‐Arruda, Michail Ignatiadis, Luc Cabel, Steven Van Laere, F Meier-Stiegen, Maria Teresa Sandri, José Vidal-Martínez, Eleni Politaki, Francesca Consoli, Daniele Generali, Maria Rosa Cappelletti, Eduardo Díaz‐Rubio, Jonathan Krell, Sarah‐Jane Dawson, Cristina Raimondi, Annemie Rutten, Wolfgang Janni, Elisabetta Munzone, Vicente Carañana, Sofia Agelaki, Camillo Almici, Luc Dirix, Erich‐Franz Solomayer, Laura Zorzino, Lauren Darrigues, Jorge S. Reis‐Filho, Lorenzo Gerratana, Stefan Michiels, François‐Clément Bidard, Klaus Pantel - Critical Reviews in Oncology/Hematology 2018 cited by 268

  24. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

    Authors: Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele - npj Breast Cancer 2022 cited by 115